Objective:

To assess the utility of the aMAP score specifically for predicting recurrence in HCC patients after radiofrequency ablation (RFA).

Approach:

Key Findings:

• 197 patients (56.3%) had a low aMAP score (≤ 63.55) and 153 patients (43.7%) had a high aMAP score (> 63.55).
• Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) (p = 0.016).
• The aMAP score is an independent prognostic factor for RFS (HR = 1.40, p = 0.028).
• Incorporation of the aMAP score into a tumor-related characteristics model improved predictive accuracy (IDI 2.6%, p = 0.036; NRI 15.9%, p = 0.036).

Interpretation:

The aMAP score is a potentially useful predictor for HCC patients undergoing RFA, significantly enhancing the predictive accuracy of existing models.

Limitations:

• Retrospective design may introduce bias, affecting the reliability of the findings.
• Single-center study limits generalizability to broader populations.
• Exclusion of certain patient groups may impact the applicability of results.

Conclusion:

The aMAP score improves the predictive accuracy for recurrence in HCC patients post-RFA.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.